The EPS beat and raised adjusted EBITDA/adjusted net income guidance are positive, but the 30% revenue decline and unchanged top-line guidance signal ongoing structural headwinds in MCM product sales. Monitor Q2 2026 revenue forecast of $170-$185M and the trajectory of Naloxone and MCM contract renewals.
Drugs in focus
EBS drug pipeline →ACAM2000
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed since 2007 (smallpox) and 2024 (mpox).
- Next catalyst
- None dated
What to watchACAM2000 is an approved, revenue-generating product with no pending FDA binary catalyst. Watch for U.S. government contract option exercises (the 10-year ASPR deal has annual renewals) and further international approvals, which drive lumpy quarterly revenue. The Q3 2026 revenue miss and lowered guidance are the near-term headwind to watch.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 1 $8.47entry
- T+1 · 7mo ago +0.83%α +1.17% · $8.54
- T+5 · 6mo ago +7.79%α +5.45% · $9.13
- T+20 · 6mo ago +0.24%α −5.05% · $8.49
- T+60 · 4mo ago −13.70%α −16.76% · $7.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Emergent BioSolutions reported Q1 2026 adjusted net income per diluted share of $0.21, beating the consensus estimate of -$0.25, but total revenues fell 30% YoY to $156.1M, below the $160.5M consensus. The company raised its full-year 2026 adjusted EBITDA guidance to $155-$175M (from $135-$155M) and adjusted net income guidance to $45-$65M (from $25-$45M), while keeping revenue guidance unchanged at $720-$760M.
Key Financial Metrics
Key Facts
- Q1 2026 total revenues of $156.1M, down 30% YoY from $222.2M
- Q1 2026 GAAP net income of $6.8M ($0.07 diluted EPS), down 90% from $68.0M ($1.19 diluted EPS)
- Adjusted net income per diluted share of $0.21, beating consensus of -$0.25
- Adjusted EBITDA of $35.6M, down 55% from $79.1M YoY
- Full-year 2026 revenue guidance unchanged at $720-$760M
- Full-year 2026 adjusted EBITDA guidance raised to $155-$175M from $135-$155M
- Full-year 2026 adjusted net income guidance raised to $45-$65M from $25-$45M
- Smallpox MCM revenue fell 40% to $64.2M; Anthrax MCM revenue fell 55% to $21.6M
- Naloxone revenue fell 5% to $42.9M
- Board authorized up to $50M in share repurchases through March 2027
- Debt refinancing with new $150M term loan facility completed in April 2026
Financial Impact
Revenue decline of $66.1M YoY (30%); adjusted EBITDA guidance raised by $20M at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Commercial Products | $42.9M | -5.3% |
| MCM Products | $101.8M | -35.0% |
Risk Factors
- Sustained revenue decline driven by lower MCM product sales to US and international governments
- Dependence on government procurement contracts with uncertain timing and funding
- High debt load ($573.6M) and interest expense ($11M in Q1) despite refinancing
- Negative operating cash flow of -$33.8M in Q1 2026
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285513 |
Track record
23 reports on EBS
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
- Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
- Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers